Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijgc.2025.101964 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revisiting the paradigm: Asymptomatic high-grade endometrial cancer diagnosis is not associated with improved outcomes.
Eur J Surg Oncol
September 2025
Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel.
Objective: To compare the survival of women with high grade endometrial cancer between asymptomatic and women presenting bleeding symptoms.
Design: An Israel Gynecologic Oncology Group multi-center retrospective cohort study.
Methods: The study included women who underwent surgery for high-grade endometrial cancer.
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53.
Transl Oncol
September 2025
The University of New Mexico, Albuquerque, NM, USA. Electronic address:
Ovarian and endometrial cancers frequently harbor a mutation in the tumor suppressor gene TP53, which occurs in over 90 % of ovarian cancers and in the most aggressive endometrial cancers. The normal tumor suppressive functions of p53 are disrupted, resulting in unregulated cell growth and therapeutic resistance to standard treatments including chemotherapy and PARP inhibitors. Hence, a novel therapeutic strategy is urgently needed for p53 mutant gynecologic cancers, and we propose that converting mutant p53 to a wild type conformation and restoring its tumor suppressive functions has the potential to greatly improve treatment.
View Article and Find Full Text PDFDistinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.
Gynecol Oncol
September 2025
Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Objective: This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.
Methods: In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.
Results: We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.
Young Women With Endometrial Cancer: A Portuguese Perspective.
Cancer Diagn Progn
September 2025
Gynecology Department, Instituto Português de Oncologia Francisco Gentil de Lisboa, Lisbon, Portugal.
Background/aim: Endometrial cancer (EC) is rare in premenopausal women. The aim of this study was to describe the demographic, clinical and pathological characteristics and compare survival in the light of pathological aspects of EC in young women.
Patients And Methods: We performed a retrospective observational cohort study, analyzing data from 29 women up to 45 years of age diagnosed between 2003 and 2023 at our Institution.
High-grade endometrioid carcinomas with pilomatrix-like features lacking CTNNB1 Mutations: Clinicopathologic characteristics and novel molecular events.
Hum Pathol
August 2025
Departments of Pathology, The International Peace Maternal and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, 200030, China. Electronic address:
Context: Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) represents a recently described, aggressive variant of endometrial carcinoma. Prior reports have linked PiMHEC with CTNNB1 exon 3 mutations and abnormal nuclear β-catenin expression.
Objective: We aimed to expand the understanding a potential subclassification of PiMHEC by analyzing three new cases that lack CTNNB1 mutations and β-catenin nuclear accumulation.